Zagotenemab (LY3303560)
Overview
Mermaid diagram (expand to render)
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Zagotenemab (LY3303560)</th>
</tr>
<tr>
<td class="label">Therapeutic</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Zagotenemab (LY3303560)</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Roche/Genentech</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">JNJ-63742057</td>
<td>Janssen</td>
</tr>
<tr>
<td class="label">Lu AF87908</td>
<td>Lundbeck</td>
</tr>
</table>
Zagotenemab (development code LY3303560) is a humanized anti-tau monoclonal antibody developed by Eli Lilly for the treatment of Alzheimer's disease["@zagotenemab"][@zagotenemaba]. It targets early pathological conformations of tau protein and was in Phase II clinical development. The therapeutic represents a significant approach to tau-directed immunotherapy, focusing on conformational rather than sequence-specific epitopes.
Background and Rationale
Tau Pathology in Alzheimer's Disease
Tau protein is a microtubule-associated protein that stabilizes neuronal axons under normal conditions. In Alzheimer's disease and related tauopathies, tau becomes hyperphosphorylated, aggregates into neurofibrillary tangles (NFTs), and spreads through connected brain regions in a characteristic pattern that correlates with clinical progression[@tau_oligomers]. The "Braak staging" system describes this spread from the entorhinal cortex to limbic regions and ultimately to isocortex as disease advances.
The tau hypothesis of AD progression proposes that pathological tau species, particularly soluble oligomers, are the primary drivers of neurotoxicity rather than the late-stage insoluble tangles. These oligomeric species are thought to propagate between neurons, seeding the aggregation of endogenous tau and driving synaptic dysfunction and neuronal loss. This mechanistic understanding created the rationale for developing antibodies that could intercept tau oligomers before they establish permanent pathology.
Traditional tau immunotherapy approaches have predominantly targeted specific phosphorylation sites (e.g., pThr181, pSer396) or linear epitopes. Zagotenemab took a different approach by targeting conformational epitopes that distinguish pathological tau aggregates from normal protein. The antibody was derived from the MCI-1 mouse monoclonal antibody, which specifically recognizes early tau aggregation intermediates rather than monomeric or fully fibrillar tau[@mci1_antibody].
This conformational targeting strategy addresses several limitations of epitope-specific approaches:
Broader coverage: Conformational epitopes may capture multiple phospho-tau species without requiring specific modification patterns
Early intervention: Antibodies targeting aggregation intermediates can intercept pathology before tangles form
Pathology-specific binding: Conformational changes are more disease-specific than phosphorylation aloneMechanism of Action
Zagotenemab is designed to bind and neutralize soluble tau aggregates that represent early pathological species[@zagotenemab][@anti_tau_mechanisms]:
- Target Epitope: Conformational epitopes on early pathological tau aggregates, specifically oligomeric species and early fibrils
- Mechanism: Binds pathological tau species in the extracellular space and possibly within the CNS, neutralizing their toxic effects and potentially facilitating clearance
- Origin: Derived from the MCI-1 mouse monoclonal antibody through humanization
- Goal: Intercept tau species before they establish permanent neurofibrillary pathology and propagate to connected brain regions
The antibody was engineered to have optimal properties for CNS penetration, including sufficient affinity for target engagement and a half-life compatible with chronic intravenous dosing. By targeting soluble aggregates rather than monomeric tau or established tangles, zagotenemab aimed to intervene at a stage where pathology might still be reversible.
Binding Characteristics
The MCI-1-derived antibody recognizes a conformational epitope present on pathological tau aggregates but not on normal monomeric tau. This specificity is crucial because:
Minimal normal function disruption: The antibody does not interfere with tau's normal role in microtubule stabilization
Disease-specific targeting: Only pathological species are bound, reducing off-target effects
Early aggregate neutralization: Oligomers and small fibrils represent the most toxic speciesClinical Development
Preclinical Development
The development of zagotenemab built on extensive preclinical characterization of the MCI-1 antibody. Studies demonstrated:
- Specific binding to tau aggregates in brain tissue from AD patients
- Lack of binding to normal tau in healthy brain
- Ability to neutralize tau oligomer-induced toxicity in cellular models
- Appropriate pharmacokinetic properties for chronic dosing
Phase I Trial
First-in-human studies characterized the safety, tolerability, and pharmacokinetics of zagotenemab in healthy volunteers and patients with Alzheimer's disease[@zagotenemab].
Trial Design: Single and multiple ascending dose study in healthy adults and early AD patients
Key Findings:
- Generally well-tolerated at all dose levels tested
- Dose-proportional pharmacokinetics
- Evidence of target engagement (plasma tau elevation consistent with antibody binding)
- No dose-limiting toxicity identified
Status: Completed
Phase II Trial (PERISCOPE-ALZ)
The Phase II PERISCOPE-ALZ trial evaluated zagotenemab in patients with early Alzheimer's disease[@zagotenemaba]:
- Enrollment: 360 participants with early AD (MCI due to AD or mild AD dementia)
- Dosing: 1,400 mg or 5,600 mg monthly intravenous doses
- Duration: 2 years (104 weeks)
- Primary Endpoint: Change from baseline on the integrated Alzheimer's Disease Rating Scale (iADRS)
- Result: Did not meet primary endpoint — no significant difference from placebo in clinical outcomes
- Biomarker Findings: Treatment caused a dose-dependent increase in plasma tau, but tau-PET was not changed
- Status: Development discontinued in October 2021
The trial's failure raised important questions about the disconnect between biomarker effects and clinical efficacy in tau immunotherapy[@tau_immunotherapy_lessons].
Analysis of Trial Outcomes
Why Did Zagotenemab Fail?
Several factors may have contributed to the negative PERISCOPE-ALZ results:
Patient selection: Participants may have had disease too advanced for intervention to be effective
Endpoint sensitivity: The iADRS may not be sensitive enough to detect treatment effects at the dose levels tested
Mechanism limitations: Conformational antibody may not adequately engage all relevant tau species in the CNS
Biomarker-clinical disconnect: While plasma tau increased (suggesting target engagement), this did not translate to clinical benefit
Tau PET insensitivity: Lack of tau-PET signal change suggests insufficient impact on established pathologyBiomarker Insights
The biomarker findings from PERISCOPE-ALZ are particularly informative[@biofluid_tau]:
- Plasma tau increase: Dose-dependent elevation suggests antibody successfully bound tau in the periphery
- No tau-PET change: Indicates the antibody did not meaningfully impact established brain tau pathology
- Interpretation: Peripheral sink effect may have dominated, with antibody binding plasma tau without sufficient CNS penetration to affect brain pathology
This pattern has been observed in other tau immunotherapy programs and highlights the challenge of achieving adequate drug concentrations in the brain parenchyma.
Scientific Impact and Lessons Learned
The zagotenemab program, despite its negative outcome, provided valuable insights for the tau immunotherapy field:
1. Biomarker Validation Challenges
The disconnect between plasma tau changes and clinical/tau-PET outcomes underscores the need for better biomarker validation. Peripheral biomarkers may not accurately reflect CNS target engagement or therapeutic effects.
2. Patient Selection
Early intervention may be critical for tau-targeting therapies. The optimal population likely requires:
- Biomarker-confirmed tau pathology (positive tau-PET or CSF markers)
- Mild or pre-symptomatic disease stage
- Minimal established neurodegeneration
3. Antibody Engineering
Achieving therapeutic concentrations in the brain remains a significant challenge. Approaches to improve CNS delivery include:
- Engineering antibodies with enhanced brain penetration
- Using transferrin receptor-mediated uptake
- Developing smaller antibody fragments
- Combination approaches with blood-brain barrier modulators
4. Target Engagement Assays
More sensitive and specific assays for CNS target engagement are needed to guide dose selection and predict clinical efficacy.
Current Status
Zagotenemab (LY3303560) development has been discontinued following the negative Phase II PERISCOPE-ALZ trial results. The program provided insights into:
- Challenges of targeting conformational tau epitopes
- Disconnect between biomarker effects and clinical efficacy
- Importance of proper patient selection for tau immunotherapy trials
- Need for improved CNS delivery for antibody-based therapies
Comparison with Other Tau Immunotherapies
All anti-tau antibody programs have faced significant challenges, with most failing to meet primary endpoints in Phase II trials. This underscores the complexity of tau-targeted therapy and the need for alternative approaches.
Future Directions
The lessons from zagotenemab and other failed tau immunotherapy programs inform current research directions:
Active vaccination: Tau-targeting vaccines (e.g., AADvac1) aim to generate endogenous antibodies with potentially better brain penetration
Small molecules: Tau aggregation inhibitors and tau degradation modulators offer alternative mechanisms
Gene therapy: AAV-delivered anti-tau constructs may achieve sustained CNS expression
Combination approaches: Dual targeting of amyloid and tau may prove more effective than either alone
Biomarker-driven trials: Enriching trials with biomarker-positive patients may improve signal detectionSee Also
- [Tau Immunotherapy](/therapeutics/anti-tau-immunotherapy-programs)
- [Tau Protein](/proteins/tau)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Alzheimer's Disease Therapeutics](/therapeutics/alzheimers-disease-therapeutics)
References
[Zagotenemab Phase 1 characterization](https://www.alzforum.org/therapeutics/zagotenemab)
[Zagotenemab Phase 2 PERISCOPE-ALZ trial results (PMID:38490123)](https://pubmed.ncbi.nlm.nih.gov/38490123/)
[Tau oligomers as propagators of neurodegeneration (PMID:24142109)](https://pubmed.ncbi.nlm.nih.gov/24142109/)
[MCI-1 anti-tau antibody characterization (PMID:21807116)](https://pubmed.ncbi.nlm.nih.gov/21807116/)
[Lessons from tau immunotherapy clinical trials (PMID:36753412)](https://pubmed.ncbi.nlm.nih.gov/36753412/)
[Biofluid tau biomarkers in Alzheimer's disease (PMID:36369897)](https://pubmed.ncbi.nlm.nih.gov/36369897/)
[Mechanisms of anti-tau antibody therapies (PMID:38049982)](https://pubmed.ncbi.nlm.nih.gov/38049982/)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [LRP1-Dependent Tau Uptake Disruption](/hypothesis/h-4dd0d19b) — <span style="color:#ffd54f;font-weight:600">0.53</span> · Target: LRP1
Pathway Diagram
The following diagram shows the key molecular relationships involving Zagotenemab (LY3303560) discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)